XML 13 R2.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
Jun. 30, 2021
Dec. 31, 2020
Current assets    
Cash and cash equivalents $ 184,186,000 $ 123,436,000
Short-term marketable securities (amortized cost of $413,965 and $564,036, respectively) 414,227,000 564,833,000
Accounts receivable, net 14,174,000 10,047,000
Inventory 18,612,000 14,063,000
Prepaid expenses and other current assets 12,530,000 14,535,000
Total current assets 643,729,000 726,914,000
Long-term assets    
Property and equipment, net 75,235,000 39,692,000
Operating lease right-of-use assets 92,067,000 99,350,000
Long-term marketable securities (amortized cost of $91,177 and $118,429, respectively) 91,131,000 118,525,000
Restricted cash 2,138,000 2,138,000
Intangible assets, net 9,383,000 10,225,000
Goodwill 118,972,000 118,972,000
Other assets 719,000 598,000
Total assets 1,033,374,000 1,116,414,000
Current liabilities    
Accounts payable 6,093,000 3,237,000
Accrued liabilities 13,539,000 13,162,000
Accrued compensation and benefits 8,630,000 11,950,000
Current portion of operating lease liabilities 4,833,000 3,529,000
Current portion of deferred revenue 83,553,000 73,319,000
Total current liabilities 116,648,000 105,197,000
Long-term liabilities    
Operating lease liabilities, less current portion 103,774,000 104,333,000
Deferred revenue, less current portion 119,642,000 163,618,000
Total liabilities 340,064,000 373,148,000
Commitments and contingencies (Note 9)
Shareholders’ equity    
Preferred stock: $0.0001 par value, 10,000,000 shares authorized at June 30, 2021 and December 31, 2020; no shares issued and outstanding at June 30, 2021 and December 31, 2020
Common stock: $0.0001 par value, 340,000,000 shares authorized at June 30, 2021 and December 31, 2020; 140,663,755 and 137,646,896 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively 14,000 14,000
Additional paid-in capital 1,294,506,000 1,253,971,000
Accumulated other comprehensive gain 216,000 893,000
Accumulated deficit (601,555,000) (511,612,000)
Total Adaptive Biotechnologies Corporation shareholders’ equity 693,181,000 743,266,000
Noncontrolling interest 129,000  
Total shareholders’ equity 693,310,000 743,266,000
Total liabilities and shareholders’ equity $ 1,033,374,000 $ 1,116,414,000